STOCK TITAN

[8-K] Zimmer Biomet Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) filed an 8-K dated 7 Aug 2025 to disclose Item 2.02 – Results of Operations and Financial Condition.

  • The company issued a press release (Exhibit 99.1) announcing its financial results for the quarter ended 30 Jun 2025; the actual figures are not included in the filing.
  • The 8-K clarifies that the press release is being furnished, not filed, thereby limiting Exchange Act liability.
  • No other material transactions, guidance changes or strategic updates are reported.

The document also lists ZBH’s registered securities (common stock and three note issues) and provides standard emerging-growth-company and signature boilerplate.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) ha presentato un 8-K datato 7 agosto 2025 per comunicare l'Elemento 2.02 – Risultati Operativi e Condizione Finanziaria.

  • L'azienda ha diffuso un comunicato stampa (Allegato 99.1) con i risultati finanziari del trimestre terminato il 30 giugno 2025; i dati effettivi non sono inclusi nel documento.
  • L'8-K specifica che il comunicato stampa è fornito, non depositato, limitando così la responsabilità ai sensi dell'Exchange Act.
  • Non sono riportate altre transazioni rilevanti, modifiche alle previsioni o aggiornamenti strategici.

Il documento elenca inoltre i titoli registrati di ZBH (azioni ordinarie e tre emissioni di obbligazioni) e include le consuete clausole per aziende in fase di crescita e la firma standard.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) presentó un 8-K con fecha 7 de agosto de 2025 para revelar el Punto 2.02 – Resultados de Operaciones y Condición Financiera.

  • La compañía emitió un comunicado de prensa (Anexo 99.1) anunciando sus resultados financieros para el trimestre finalizado el 30 de junio de 2025; las cifras reales no están incluidas en el documento.
  • El 8-K aclara que el comunicado se proporciona, no se presenta, limitando así la responsabilidad bajo la Exchange Act.
  • No se reportan otras transacciones materiales, cambios en las previsiones ni actualizaciones estratégicas.

El documento también enumera los valores registrados de ZBH (acciones comunes y tres emisiones de notas) y ofrece las cláusulas estándar para empresas emergentes y la firma habitual.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH)는 2025년 8월 7일자 8-K를 제출하여 항목 2.02 – 영업실적 및 재무상태 결과를 공시했습니다.

  • 회사는 2025년 6월 30일 종료된 분기 재무 결과를 발표하는 보도자료(첨부문서 99.1)를 발행했으나, 실제 수치는 공시서류에 포함되지 않았습니다.
  • 8-K 문서는 보도자료가 제출된 것이 아니라 제공된 것임을 명확히 하여 Exchange Act에 따른 책임을 제한합니다.
  • 기타 중요한 거래, 전망 변경 또는 전략적 업데이트는 보고되지 않았습니다.

문서에는 ZBH의 등록 증권(보통주 및 세 건의 채권 발행)이 나열되어 있으며, 신생 성장 기업 및 서명 관련 표준 문구도 포함되어 있습니다.

Zimmer Biomet Holdings, Inc. (NYSE : ZBH) a déposé un 8-K daté du 7 août 2025 pour divulguer l’élément 2.02 – Résultats d’exploitation et situation financière.

  • La société a publié un communiqué de presse (Annexe 99.1) annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025 ; les chiffres réels ne sont pas inclus dans le dépôt.
  • Le 8-K précise que le communiqué est fourni, mais pas déposé, limitant ainsi la responsabilité au titre de l’Exchange Act.
  • Aucune autre transaction importante, modification des prévisions ou mise à jour stratégique n’est rapportée.

Le document liste également les titres enregistrés de ZBH (actions ordinaires et trois émissions d’obligations) et fournit les clauses types pour les entreprises en croissance ainsi que la signature standard.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) reichte am 7. August 2025 ein 8-K ein, um Punkt 2.02 – Betriebsergebnisse und Finanzlage offenzulegen.

  • Das Unternehmen veröffentlichte eine Pressemitteilung (Anlage 99.1) mit den Finanzergebnissen für das Quartal zum 30. Juni 2025; die tatsächlichen Zahlen sind nicht in der Einreichung enthalten.
  • Das 8-K stellt klar, dass die Pressemitteilung bereitgestellt und nicht eingereicht wird, wodurch die Haftung nach dem Exchange Act eingeschränkt wird.
  • Es werden keine weiteren wesentlichen Transaktionen, Prognoseänderungen oder strategischen Updates gemeldet.

Das Dokument listet außerdem die registrierten Wertpapiere von ZBH (Stammaktien und drei Anleihen) auf und enthält die üblichen Standardklauseln für wachstumsstarke Unternehmen sowie die Unterschriftsformulare.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine 8-K furnishing an earnings press release; no numbers, neutral impact.

The filing simply alerts investors that Zimmer Biomet’s Q2-25 results are available in a separate press release. Because no revenue, EPS or guidance data are presented, the 8-K itself offers minimal analytical value. Liability is limited by furnishing status, a common practice. Market reaction will hinge on the content of Exhibit 99.1, not this notice. I therefore assign a neutral impact rating.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) ha presentato un 8-K datato 7 agosto 2025 per comunicare l'Elemento 2.02 – Risultati Operativi e Condizione Finanziaria.

  • L'azienda ha diffuso un comunicato stampa (Allegato 99.1) con i risultati finanziari del trimestre terminato il 30 giugno 2025; i dati effettivi non sono inclusi nel documento.
  • L'8-K specifica che il comunicato stampa è fornito, non depositato, limitando così la responsabilità ai sensi dell'Exchange Act.
  • Non sono riportate altre transazioni rilevanti, modifiche alle previsioni o aggiornamenti strategici.

Il documento elenca inoltre i titoli registrati di ZBH (azioni ordinarie e tre emissioni di obbligazioni) e include le consuete clausole per aziende in fase di crescita e la firma standard.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) presentó un 8-K con fecha 7 de agosto de 2025 para revelar el Punto 2.02 – Resultados de Operaciones y Condición Financiera.

  • La compañía emitió un comunicado de prensa (Anexo 99.1) anunciando sus resultados financieros para el trimestre finalizado el 30 de junio de 2025; las cifras reales no están incluidas en el documento.
  • El 8-K aclara que el comunicado se proporciona, no se presenta, limitando así la responsabilidad bajo la Exchange Act.
  • No se reportan otras transacciones materiales, cambios en las previsiones ni actualizaciones estratégicas.

El documento también enumera los valores registrados de ZBH (acciones comunes y tres emisiones de notas) y ofrece las cláusulas estándar para empresas emergentes y la firma habitual.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH)는 2025년 8월 7일자 8-K를 제출하여 항목 2.02 – 영업실적 및 재무상태 결과를 공시했습니다.

  • 회사는 2025년 6월 30일 종료된 분기 재무 결과를 발표하는 보도자료(첨부문서 99.1)를 발행했으나, 실제 수치는 공시서류에 포함되지 않았습니다.
  • 8-K 문서는 보도자료가 제출된 것이 아니라 제공된 것임을 명확히 하여 Exchange Act에 따른 책임을 제한합니다.
  • 기타 중요한 거래, 전망 변경 또는 전략적 업데이트는 보고되지 않았습니다.

문서에는 ZBH의 등록 증권(보통주 및 세 건의 채권 발행)이 나열되어 있으며, 신생 성장 기업 및 서명 관련 표준 문구도 포함되어 있습니다.

Zimmer Biomet Holdings, Inc. (NYSE : ZBH) a déposé un 8-K daté du 7 août 2025 pour divulguer l’élément 2.02 – Résultats d’exploitation et situation financière.

  • La société a publié un communiqué de presse (Annexe 99.1) annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025 ; les chiffres réels ne sont pas inclus dans le dépôt.
  • Le 8-K précise que le communiqué est fourni, mais pas déposé, limitant ainsi la responsabilité au titre de l’Exchange Act.
  • Aucune autre transaction importante, modification des prévisions ou mise à jour stratégique n’est rapportée.

Le document liste également les titres enregistrés de ZBH (actions ordinaires et trois émissions d’obligations) et fournit les clauses types pour les entreprises en croissance ainsi que la signature standard.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) reichte am 7. August 2025 ein 8-K ein, um Punkt 2.02 – Betriebsergebnisse und Finanzlage offenzulegen.

  • Das Unternehmen veröffentlichte eine Pressemitteilung (Anlage 99.1) mit den Finanzergebnissen für das Quartal zum 30. Juni 2025; die tatsächlichen Zahlen sind nicht in der Einreichung enthalten.
  • Das 8-K stellt klar, dass die Pressemitteilung bereitgestellt und nicht eingereicht wird, wodurch die Haftung nach dem Exchange Act eingeschränkt wird.
  • Es werden keine weiteren wesentlichen Transaktionen, Prognoseänderungen oder strategischen Updates gemeldet.

Das Dokument listet außerdem die registrierten Wertpapiere von ZBH (Stammaktien und drei Anleihen) auf und enthält die üblichen Standardklauseln für wachstumsstarke Unternehmen sowie die Unterschriftsformulare.

false00011368690001136869zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember2025-08-072025-08-0700011368692025-08-072025-08-070001136869zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember2025-08-072025-08-070001136869us-gaap:CommonStockMember2025-08-072025-08-070001136869zbh:ThreePointFiveOneEightPercentageNotesDueTwoThousandThirtyTwoMember2025-08-072025-08-07

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2025

 

 

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-16407

13-4151777

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

345 East Main Street

 

Warsaw, Indiana

 

46580

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (574) 373-3333

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value

 

ZBH

 

New York Stock Exchange

2.425% Notes due 2026

 

ZBH 26

 

New York Stock Exchange

1.164% Notes due 2027

 

ZBH 27

 

New York Stock Exchange

3.518% Notes due 2032

 

ZBH 32

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 2.02 Results of Operations and Financial Condition.

 

On August 7, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

 

The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d)
Exhibits

 

EXHIBIT INDEX

Exhibit No.

 

Description

99.1

 

Press release dated August 7, 2025

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 7, 2025

 

 

ZIMMER BIOMET HOLDINGS, INC.

 

 

 

 

By:

/s/ Chad F. Phipps

 

Name:

Chad F. Phipps

 

Title:

Senior Vice President, General Counsel
and Secretary

 

 

 

 


FAQ

What did Zimmer Biomet disclose in its 8-K dated August 7 2025?

The company furnished a press release (Exhibit 99.1) reporting financial results for the quarter ended June 30 2025.

Are actual Q2 2025 financial figures included in the 8-K?

No. The 8-K references the press release but does not reproduce revenue, EPS or other metrics.

Does the filing impose Exchange Act liability for the earnings data?

No. The information is furnished, not filed, under Item 2.02, limiting Section 18 liability.

Which securities of Zimmer Biomet are listed in the filing?

Common stock (ZBH) and notes due 2026 (2.425%), 2027 (1.164%), and 2032 (3.518%), all traded on NYSE.

Where can investors find the detailed Q2 2025 results?

In Exhibit 99.1, the press release dated August 7 2025, which accompanies the 8-K filing.
Zimmer Biomet

NYSE:ZBH

ZBH Rankings

ZBH Latest News

ZBH Latest SEC Filings

ZBH Stock Data

18.21B
197.53M
0.15%
96.22%
3.71%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WARSAW